BVD vaccination in cattle: fetal protection against bovine viral diarrhea virus — LIKELY

In pregnant cattle, does bovine viral diarrhea virus (BVDV) vaccination before breeding protect the fetus against BVDV infection and persistent infection, compared with no vaccination or placebo vaccination?

Shelf #36 · gate-verified and displayed under the developer's blinded-trial rule

LIKELY: BVDV vaccination before breeding substantially protects the fetus, across modified-live and killed vaccines, dosed challenge and natural exposure to persistently infected cattle — but protection is incomplete, and that limit is on the face of this shelf. In the placebo-controlled trial, an MLV vaccine reduced the fetal infection rate by at least 82% for type 1 and 75% for type 2 in relative terms, with type 2 virus isolated from 2/28 vaccinated fetuses vs 17/18 control fetuses and type 1 virus from 0/22 vaccinated calves vs 5/12 controls (Xue 2009). In the early-gestation window where persistent infection is established, persistently infected calves came from 2/12 vaccinated heifers vs 6/6 controls after heterologous type 1 challenge (Cortese 1998); exposure to persistently infected cattle left all 10/10 control heifers infected vs fetal protection in 17/20 vaccinated heifers by either route (Leyh 2011); and killed type 1c/1a vaccines left 4/14 and 3/8 fetuses PCR-positive vs 15/15 unvaccinated (Packianathan 2017, relative prevented fractions 71.4% and 62.5%). The stamp is LIKELY rather than higher because every programme still produced infected fetuses from vaccinated heifers, group sizes are small, and all evidence is challenge/exposure studies in heifers rather than field eradication outcomes. Design class (a): a carded record establishes both randomisation and a placebo control (Xue 2009 — Random Allocation in the record's MeSH and placebo-vaccine controls in its abstract), and the fetal-protection claim rests in part on it. Drafted Nov 10, 2026 (VetMed build, topic #36); all figures from abstracts fetched and verified at drafting.

Xue 2009: a modified-live BVDV vaccine reduced fetal infection by at least 82% (type 1) and 75% (type 2) in relative terms after challenge at ~170 days' gestation — type 2 virus was isolated from 17/18 control fetuses vs 2/28 vaccinated fetuses, and type 1 virus from 5/12 control calves vs 0/22 vaccinated calves

Vaccination–challenge trial with placebo-vaccine controls (record's MeSH includes Random Allocation; publication types: Journal Article)

Who: Cattle — pregnant heifers: 83 heifers vaccinated with a modified-live virus (MLV) vaccine or a placebo vaccine, bred naturally 4 weeks after vaccination, and challenged at approximately 170 days of gestation with noncytopathic field isolates of bovine viral diarrhea virus (BVDV) type 1 or type 2; fetuses were collected 60 days after type 2 challenge, and newborn calves were collected before colostrum intake after type 1 challenge, with protection measured by fetal/calf serum neutralizing antibody response and virus isolation from thymus, lung, spleen and kidney.

Result: There was a measurable serum neutralizing antibody response in all fetuses and calves of the placebo (control) heifers, but only 4 of 22 calves and 7 of 28 fetuses of MLV-vaccinated heifers demonstrated serum neutralizing antibody after challenge. Type 1 BVDV was isolated from tissue samples of 5 of the 12 calves of control heifers and none of 22 calves of MLV-vaccinated heifers challenged with type 1 BVDV. Type 2 BVDV was isolated from tissue samples of 17 of the 18 fetuses of control heifers and 2 of the 28 fetuses of MLV-vaccinated heifers challenged with type 2 BVDV. The authors conclude the MLV vaccine reduces the fetal infection rate by at least 82% for BVDV type 1 and by 75% for BVDV type 2 — relative reductions, stated alongside the absolute isolation counts above — when heifers are exposed to highly fetotrophic BVDV at 170 days of gestation.

Watch out: Correction to the map anchor: this paper appeared in the Canadian Journal of Veterinary Research (Can J Vet Res), not the Canadian Veterinary Journal as the map stated. Challenge was at ~170 days' gestation — late gestation, after the window in which persistent infection is established — so this trial speaks to fetal infection at that stage; the early-gestation persistent-infection question is carried by the Cortese 1998 card. The record's randomisation evidence is its MeSH Random Allocation term and its placebo-vaccine control; assessor masking is not separately described in the abstract.

Xue W, Mattick D, Smith L, Maxwell J. Fetal protection against bovine viral diarrhea virus types 1 and 2 after the use of a modified-live virus vaccine. Can J Vet Res. 2009;73(4):292-7. PMID: 20046631. Registry ID: none in the record. MeSH: Animals · Animals, Newborn · Antibodies, Viral/blood · Bovine Virus Diarrhea-Mucosal Disease/*immunology,*prevention & control · Cattle · Diarrhea Virus 1, Bovine Viral/*immunology · Diarrhea Virus 2, Bovine Viral/*immunology · Female · Fetus · Neutralization Tests/veterinary · Pregnancy · Pregnancy Complications, Infectious/prevention & control,veterinary,virology · Random Allocation · Vaccines, Attenuated/administration & dosage,immunology · Viral Vaccines/*administration & dosage,immunology

Cortese 1998: after heterologous type 1 challenge at 70–75 days' gestation, persistently infected calves came from 6/6 control heifers vs 2/12 heifers vaccinated with a modified-live NADL-strain vaccine

Randomized controlled cohort study (record's own design wording; publication types include Randomized Controlled Trial)

Who: Cattle — yearling beef heifers: 18 heifers seronegative for BVDV and negative on virus isolation, randomly assigned to control (unvaccinated, n = 6) or vaccinated (n = 12) groups; vaccinated heifers received a single dose of a combination vaccine containing modified-live BVDV type 1 (cytopathic NADL strain), all 18 were then bred and challenge-exposed intranasally between 70 and 75 days of gestation with heterologous BVDV type 1, and the infection status of the offspring was determined after parturition.

Result: All 6 calves from control heifers had positive results on multiple virus isolation tests and were considered persistently infected (6/6, 100%). In comparison, only 2 calves from vaccinated cows had positive virus isolation results and were considered persistently infected (2/12, 17%) — an absolute difference of 83 percentage points. One vaccinated heifer aborted, but the fetus was not persistently infected and the abortion was not attributed to BVDV infection. The authors concluded a single dose of the modified-live NADL-derived type 1 vaccine conferred protection to dams and their fetuses against heterologous type 1 challenge.

Watch out: Protection was incomplete — 2 of 12 vaccinated heifers still produced persistently infected calves — and the numbers are small (6 controls), so the 100% vs 17% contrast is stark but imprecise. Controls were unvaccinated rather than placebo-treated, and blinding is not stated in the record. Challenge was a single heterologous type 1 strain at 70–75 days' gestation, the classic persistent-infection window.

Cortese VS, Grooms DL, Ellis J, Bolin SR, Ridpath JF, Brock KV. Protection of pregnant cattle and their fetuses against infection with bovine viral diarrhea virus type 1 by use of a modified-live virus vaccine. Am J Vet Res. 1998;59(11):1409-13. PMID: 9829398. Registry ID: none in the record. MeSH: Animals · Base Sequence · Bovine Virus Diarrhea-Mucosal Disease/*prevention & control,transmission · Cattle · Cohort Studies · DNA, Viral/chemistry · Diarrhea Virus 1, Bovine Viral/*immunology · Female · Fetal Diseases/prevention & control · Infectious Disease Transmission, Vertical · Molecular Sequence Data · Neutralization Tests · Pregnancy · Pregnancy Complications, Infectious/prevention & control,*veterinary · Pregnancy, Animal/*immunology · Sequence Alignment · Sequence Analysis, DNA · Vaccination/veterinary · Vaccines, Combined/immunology · *Viral Vaccines/immunology

Leyh 2011: heifers vaccinated once with a modified-live 1a/2a vaccine before breeding were protected against fetal infection in 17/20 (intramuscular) and 17/20 (subcutaneous) after exposure to persistently infected cattle, while all 10/10 control heifers were considered infected

Vaccination–exposure trial with placebo-vaccine controls (record's publication types: Journal Article; no randomisation stated in the abstract)

Who: Cattle — heifers and their fetuses: 50 pregnant heifers (20 vaccinated subcutaneously, 20 vaccinated intramuscularly with an MLV vaccine containing BVDV subtypes 1a and 2a, and 10 controls given a placebo vaccine intramuscularly), challenge-exposed on day 124 (at 64 to 89 days of gestation) to 8 cattle persistently infected (PI) with BVDV subtype 1b, with fetuses recovered on days 207 to 209 for virus isolation and immunohistochemistry.

Result: Two control heifers aborted after challenge exposure and both fetuses were unavailable for testing. Eleven fetuses (8 from control heifers, 1 from an intramuscular vaccinate and 2 from subcutaneous vaccinates) were positive for BVDV by virus isolation and immunohistochemistry in multiple tissues, with three additional vaccinate fetuses considered exposed — one intramuscular fetus was seropositive for BVDV, one intramuscular fetus was positive by virus isolation in fetal tissues, and one subcutaneous fetus was positive by virus isolation from serum alone. Counting all criteria, vaccination provided fetal protection in 17/20 intramuscular and 17/20 subcutaneous heifers, but all control heifers (10/10) were considered infected. The authors concluded one dose of the 1a/2a MLV vaccine, given subcutaneously or intramuscularly before breeding, helped protect against fetal infection in heifers exposed to PI cattle carrying subtype 1b.

Watch out: Exposure here was contact with PI cattle — the natural route — rather than a dosed intranasal challenge, which strengthens realism but makes exposure dose uneven; two control fetuses were lost to abortion and could not be tested, and the 'considered infected/protected' totals combine virus isolation, antigen and serology criteria, so the 17/20 figures are the authors' composite, not a single-test count. The abstract does not state that heifers were randomly allocated, and randomisation is not claimed for this card.

Leyh RD, Fulton RW, Stegner JE, Goodyear MD, Witte SB, Taylor LP, Johnson BJ, Step DL, Ridpath JF, Holland BP. Fetal protection in heifers vaccinated with a modified-live virus vaccine containing bovine viral diarrhea virus subtypes 1a and 2a and exposed during gestation to cattle persistently infected with bovine viral diarrhea virus subtype 1b. Am J Vet Res. 2011;72(3):367-75. PMID: 21355740. Registry ID: none in the record. MeSH: Animals · Antibodies, Viral/blood · Bovine Virus Diarrhea-Mucosal Disease/*prevention & control · Cattle · Diarrhea Virus 1, Bovine Viral/*immunology · Diarrhea Virus 2, Bovine Viral/*immunology · Female · Immunity, Maternally-Acquired · Infectious Disease Transmission, Vertical/prevention & control,*veterinary · Pregnancy · Pregnancy Complications, Infectious/prevention & control,*veterinary · Vaccines, Attenuated/administration & dosage,immunology · Viral Vaccines/*immunology

Packianathan 2017: killed type 1c and type 1a vaccines both reduced fetal infection after type 1a exposure — virus detected in 15/15 fetuses of unvaccinated heifers vs 4/14 (type 1c vaccine) and 3/8 (type 1a vaccine); prevented fractions 71.4% and 62.5% (relative)

Randomized controlled trial (record's own publication types include Randomized Controlled Trial; abstract states heifers were randomly allocated)

Who: Cattle — crossbred Friesian heifers: 55 heifers free from BVD virus and antibody, randomly allocated to a vaccine containing type 1c BVD virus given twice (n = 25), a vaccine containing type 1a BVD virus (n = 10), or no vaccination (n = 20); after breeding, 15 heifers from the type 1c group, 8 from the type 1a group and 15 unvaccinated heifers were exposed for 4 weeks to four calves persistently infected with type 1a BVD virus, starting when 36/38 were 72–74 days pregnant, and fetal tissues were collected about 52 days after the start of challenge for ELISA and PCR detection of BVD virus.

Result: Based on PCR results, BVD virus was detected in 15/15 fetuses in the unvaccinated group, compared with 4/14 fetuses in the type 1c group and 3/8 fetuses in the type 1a group; the proportion of virus-positive fetuses was lower in both vaccinated groups than in unvaccinated heifers (P < 0.002), with no difference between the two vaccinated groups (P = 1.00). Fetal protection, expressed as the prevented fraction, was 71.4% (95% CI = 41.9–91.6%) for the type 1c vaccine and 62.5% (95% CI = 24.5–91.5%) for the type 1a vaccine — relative prevented fractions, with the absolute counts given above. The authors conclude prevention of fetal infection by vaccination may not be 100%, and the risk of persistently infected calves being born to some vaccinated cattle should be acknowledged and managed as part of a BVD control programme.

Watch out: These are killed (inactivated) vaccines, unlike the modified-live products on the other cards — the fetal-protection claim on this shelf is not MLV-only. Only a subset of the allocated heifers entered the challenge phase (15, 8 and 15), one type 1c fetus is missing from the PCR denominator (4/14 of 15 challenged), and the confidence intervals on the prevented fractions are wide. Controls were unvaccinated rather than placebo-treated; blinding is not stated in the record.

Packianathan R, Clough WJ, Hodge A, Holz DK, Huang J, Bryant GL, Colantoni C. Prevention of fetal infection in heifers challenged with bovine viral diarrhoea virus type 1a by vaccination with a type 1c or type 1a vaccine. N Z Vet J. 2017;65(3):134-139. PMID: 28359226. Registry ID: none in the record. MeSH: Animals · Antibodies, Viral/blood,metabolism · Bovine Virus Diarrhea-Mucosal Disease/*prevention & control,transmission · Cattle · Diarrhea Virus 1, Bovine Viral/*classification,immunology · Female · Fetus/immunology · Infectious Disease Transmission, Vertical/prevention & control,*veterinary · Pregnancy · Viral Vaccines/*immunology

Synthesis: BVDV vaccination before breeding substantially protects the fetus across challenge designs and vaccine types — but protection is not complete, and persistently infected calves were still born to vaccinated heifers in every programme

Synthesis

Who: Synthesis of the cards above, all in cattle (pregnant heifers): Xue 2009 (83 heifers, MLV vs placebo vaccine, dosed challenge at ~170 days' gestation, types 1 and 2), Cortese 1998 (18 heifers, randomised, MLV type 1, challenge at 70–75 days), Leyh 2011 (50 heifers, MLV 1a/2a vs placebo vaccine, exposure to persistently infected cattle at 64–89 days) and Packianathan 2017 (55 heifers, randomised, killed type 1c or 1a vaccines, exposure to persistently infected calves at ~72–74 days).

Result: (1) Fetal infection by virus isolation: type 2, 2/28 vaccinated vs 17/18 control fetuses, and type 1, 0/22 vaccinated vs 5/12 control calves (Xue), with the authors' stated relative reductions in fetal infection rate of at least 82% (type 1) and 75% (type 2). (2) Persistent infection after early-gestation type 1 challenge: 2/12 calves from vaccinated heifers vs 6/6 from controls (Cortese). (3) Natural PI-cattle exposure: fetal protection in 17/20 heifers by either vaccination route vs 10/10 controls considered infected (Leyh), and PCR-positive fetuses in 4/14 and 3/8 with killed vaccines vs 15/15 unvaccinated (Packianathan; relative prevented fractions 71.4% and 62.5%). (4) In every carded programme at least some vaccinated heifers carried infected fetuses — vaccination reduces fetal infection substantially; it does not abolish it.

Watch out: All four are challenge/exposure studies in heifers, not field trials measuring herd-level BVD eradication, calf survival to weaning, or duration of fetal protection across later pregnancies; group sizes are small (6–28 per arm) and challenge timing, virus subtype and vaccine type differ across cards. Xue's challenge at ~170 days' gestation tests late-gestation fetal infection, while Cortese, Leyh and Packianathan test the early-gestation window in which persistent infection is established.

Synthesis of Xue W et al. PMID: 20046631; Cortese VS et al. PMID: 9829398; Leyh RD et al. PMID: 21355740; Packianathan R et al. PMID: 28359226. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.